Education
About Us
Working with TipRanks
Follow Us
Strides Pharma Science Ltd (IN:STAR)
:STAR
STAR Stock Chart & Stats
₹950.75
-₹13.60(-1.99%)
At close: 4:00 PM EST
₹950.75
-₹13.60(-1.99%)
Day’s Range― - ―
52-Week Range₹551.00 - ₹1,024.90
Previous CloseN/A
Volume639.08K
Average Volume (3M)12.54K
Market Cap
₹77.67B
Enterprise Value₹94.66B
Total Cash (Recent Filing)₹1.99B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)15.2
Beta1.22
Next Earnings
May 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.41%
Share Statistics
EPS (TTM)21.90
Shares Outstanding92,172,714
10 Day Avg. Volume13,417
30 Day Avg. Volume12,536
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.40
Price to Sales (P/S)1.33
P/FCF Ratio13.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)57.97
Revenue Forecast (FY)₹48.84B
Bulls Say, Bears Say
Bulls Say
Strong Free Cash Flow GenerationConsistent conversion of earnings into free cash flow improves financial resilience and funds capital spending, regulatory compliance, and working capital without reliance on external financing. This durable cash generation supports reinvestment in manufacturing capacity and product development over several quarters.
Improving Revenue And MarginsSustained improvement in revenue and gross/net margins signals operational efficiency gains and a healthier product mix. If maintained, higher margins enhance cash generation and buffer against pricing pressure in generics, enabling longer-term investments in R&D and capacity expansion.
Diversified Pharma Revenue StreamsMultiple revenue pillars—finished dosage sales, contract manufacturing, and licensing—reduce reliance on any single market or product. This structural diversification smooths cash flows across product lifecycles, supports scale utilization of in-house manufacturing, and provides multiple paths for sustainable growth.
Bears Say
Historical Earnings VolatilityPast swings into negative EBIT/EBITDA indicate execution and margin risk that can persist through product lifecycle shifts or tender losses. Such volatility undermines predictability for capex planning and sustained R&D spend, increasing the difficulty of delivering stable long-term cash flows and returns.
Balance Sheet And Cash Position ConstraintsA moderate debt load and weaknesses in cash reserves constrain financial flexibility, limiting the company's ability to fund large capacity builds, absorb regulatory setbacks, or pursue acquisitions. Over time this can increase refinancing risk and reduce ability to seize strategic opportunities.
Dependence On Regulatory Approvals And ScaleBusiness growth hinges on successful regulatory filings, timely approvals, and scalable manufacturing. These structural execution risks involve long lead times, inspection and compliance hurdles, and capital intensity—any delays or inspection findings can materially impair product launches and revenue durability.
Strides Pharma Science Ltd News
STAR FAQ
What was Strides Pharma Science Ltd’s price range in the past 12 months?
Strides Pharma Science Ltd lowest stock price was ₹551.00 and its highest was ₹1024.90 in the past 12 months.
What is Strides Pharma Science Ltd’s market cap?
Strides Pharma Science Ltd’s market cap is ₹77.67B.
When is Strides Pharma Science Ltd’s upcoming earnings report date?
Strides Pharma Science Ltd’s upcoming earnings report date is May 21, 2026 which is in 77 days.
How were Strides Pharma Science Ltd’s earnings last quarter?
Strides Pharma Science Ltd released its earnings results on Jan 30, 2026. The company reported ₹21.9 earnings per share for the quarter, beating the consensus estimate of N/A by ₹21.9.
Is Strides Pharma Science Ltd overvalued?
According to Wall Street analysts Strides Pharma Science Ltd’s price is currently Overvalued.
Does Strides Pharma Science Ltd pay dividends?
Strides Pharma Science Ltd pays a Annually dividend of ₹4 which represents an annual dividend yield of 0.41%. See more information on Strides Pharma Science Ltd dividends here
What is Strides Pharma Science Ltd’s EPS estimate?
Strides Pharma Science Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Strides Pharma Science Ltd have?
Strides Pharma Science Ltd has 92,172,714 shares outstanding.
What happened to Strides Pharma Science Ltd’s price movement after its last earnings report?
Strides Pharma Science Ltd reported an EPS of ₹21.9 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 8.492%.
Which hedge fund is a major shareholder of Strides Pharma Science Ltd?
Currently, no hedge funds are holding shares in IN:STAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Strides Pharma Science Ltd
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.
Technical Analysis
Alkem Laboratories Ltd.
―
Aurobindo Pharma Ltd
―
Glenmark Pharmaceuticals Limited
―
IPCA Laboratories Limited
―
Laurus Labs Ltd.
―